Swiss pharmaceutical company Novartis said Friday it has won approval to market its Cosentyx psoriasis treatment in Japan, making it the first country to authorise commercialisation of the drug. The Japanese decision allows Novartis to sell secukinumab, sold under the name Cosentyx, to adult patients suffering psoriasis vulgaris and psoriatic arthritis, and who aren't responding to other medication. It's estimated 3 percent of the world's population -- or over 125 million people -- suffer from some form of psoriasis, including over 400,000 individuals in Japan alone. Psoriasis vulgaris is a skin disease provoking thick, itchy lesions, while the articular variant causes stiffness and pain in joints.
via Health News Headlines - Yahoo News http://ift.tt/1wOtBy3
No comments:
Post a Comment